These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 11856618)

  • 1. Development of hepatitis B virus resistance for lamivudine in chronic hepatitis B patients co-infected with the human immunodeficiency virus in a Dutch cohort.
    Wolters LM; Niesters HG; Hansen BE; van der Ende ME; Kroon FP; Richter C; Brinkman K; Meenhorst PL; de Man RA
    J Clin Virol; 2002 Apr; 24(3):173-81. PubMed ID: 11856618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
    Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
    Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
    Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
    J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [YMDD motif variants detected by Inno-Lipa HBV DR assay in chronic hepatitis B patients during lamivudine therapy].
    Arslan U; Ural O; Findik D
    Mikrobiyol Bul; 2008 Jul; 42(3):445-50. PubMed ID: 18822888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
    J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrasting patterns of response to lamivudine monotherapy in chronic hepatitis B patients.
    Wolters LM; van Nunen AB; Niesters HG; de Man RA
    Scand J Gastroenterol Suppl; 2000; (232):74-8. PubMed ID: 11232497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
    Smit MC; Haverkamp MH; Weersink AJ; Boucher CA; Hoepelman IM
    Ned Tijdschr Geneeskd; 2004 Nov; 148(47):2330-4. PubMed ID: 15587052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
    Santos EA; Sucupira MV; Arabe J; Gomes SA
    BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
    Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
    Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
    Benhamou Y; Thibault V; Vig P; Calvez V; Marcelin AG; Fievet MH; Currie G; Chang CG; Biao L; Xiong S; Brosgart C; Poynard T
    J Hepatol; 2006 Jan; 44(1):62-7. PubMed ID: 16274835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men.
    Benhamou Y; Katlama C; Lunel F; Coutellier A; Dohin E; Hamm N; Tubiana R; Herson S; Poynard T; Opolon P
    Ann Intern Med; 1996 Nov; 125(9):705-12. PubMed ID: 8929003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
    Amponsah-Dacosta E; Rakgole JN; Gededzha MP; Lukhwareni A; Blackard JT; Selabe SG; Mphahlele MJ
    Infect Genet Evol; 2016 Sep; 43():232-8. PubMed ID: 27245151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan.
    Suzuki F; Tsubota A; Arase Y; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Takagi K; Kumada H
    Intervirology; 2003; 46(3):182-9. PubMed ID: 12867757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.
    Nelson M; Portsmouth S; Stebbing J; Atkins M; Barr A; Matthews G; Pillay D; Fisher M; Bower M; Gazzard B
    AIDS; 2003 Jan; 17(1):F7-10. PubMed ID: 12478090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
    Sasadeusz J; Audsley J; Mijch A; Baden R; Caro J; Hunter H; Matthews G; McMahon MA; Olender SA; Siliciano RF; Lewin SR; Thio CL
    AIDS; 2008 May; 22(8):947-55. PubMed ID: 18453854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.
    Libbrecht E; Doutreloigne J; Van De Velde H; Yuen MF; Lai CL; Shapiro F; Sablon E
    J Clin Microbiol; 2007 Dec; 45(12):3935-41. PubMed ID: 17913933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.
    Lok AS; Zoulim F; Locarnini S; Mangia A; Niro G; Decraemer H; Maertens G; Hulstaert F; De Vreese K; Sablon E
    J Clin Microbiol; 2002 Oct; 40(10):3729-34. PubMed ID: 12354872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation.
    Pas SD; de Man RA; Fries E; Osterhaus AD; Niesters HG
    J Clin Virol; 2002 Jul; 25(1):63-71. PubMed ID: 12126723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.